Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“The future of cancer research has never looked brighter.
Delighted to deliver the opening plenary, ‘Rethinking the Rules of Drug Development,‘ for the Stanford Cancer Institute and Stanford University’s Stanford Comprehensive Cancer Research Training Program.
Energized by the next generation of innovators and researchers pushing boundaries.
Our collaboration is unprecedented and the Tumor Agnostic, PrecisionMedicine momentum continues across institutions and is zip‑code agnostic.”
Other articles about Stanford Cancer Institute on OncoDaily.
